engleski

First experience of alpelisib treatment of HR+ HER2- metastatic breast carcinoma in Croatia

The median age of patients is 67 years. All three patients received numerous (min 4, max 11) therapies for metastatic breast cancer. All three of them previously received CDKi + hormone therapy (HT). Patients have recived alpelisib therapy for medium time of 4 months. Only one patient, who was prediabetic before the start of alpelisib, developed hyperglycaemia gr 3. With the introduction of antidia-betic therapy (SGLT2 inhibitor, pioglitazone and diabetic diet), blood glucose levels were reduced. A decrease of the Ca 15.3 tumour marker was noted in all three patients. Two patients reported weight loss of gr I. There were no other side effects.

metastatic breast cancer ; PIK3Ca mutation ; Alpelisib

nije evidentirano